Daniel Orenstein - Nov 1, 2021 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Role
General Counsel
Signature
/s/ Daniel Orenstein
Stock symbol
HCAT
Transactions as of
Nov 1, 2021
Transactions value $
-$108,108
Form type
4
Date filed
11/2/2021, 04:30 PM
Previous filing
Oct 5, 2021
Next filing
Dec 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCAT Common Stock Options Exercise $25.9K +2.5K +3.31% $10.34 78K Nov 1, 2021 Direct
transaction HCAT Common Stock Sale -$126K -2.36K -3.02% $53.55 75.7K Nov 1, 2021 Direct F1, F2
transaction HCAT Common Stock Sale -$7.62K -141 -0.19% $54.07 75.5K Nov 1, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCAT Stock Option (Right to Buy) Options Exercise $0 -2.5K -2.02% $0.00 121K Nov 1, 2021 Common Stock 2.5K $10.34 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 4, 2021, in accordance with Rule 10b5-1.
F2 Represents the weighted average sale price of the shares sold ranging from $53.05 to $54.04 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
F3 25% of the 136,316 shares underlying the options vested in an annual installment on December 31, 2016 and the remaining balance vested in equal monthly installments until the option vested in full on Dec. 31, 2019.